current user: public
If you have questions about the server, please let us know.

Query: [O] COG5533 Ubiquitin C-terminal hydrolase, from COG1018

Results of FFAS03 search in COG1018
Master-slave alignment(slide right to see more) does not show gaps in the query sequence, use ali links to display alignment between query and templates.
    .   10    .   20    .   30    .   40    .   50    .   60    .   70    .   80    .   90    .  100    .  110    .  120    .  130    .  140    .  150    .  160    .  170    .  180    .  190    .  200    .  210    .  220    .  230    .  240    .  250    .  260    .  270    .  280    .  290    .  300    .  310    .  320    .  330    .  340    .  350    .  360    .  370    .  380    .  390    .  400    .  410    .  420    .  430    .  440    .  450    .  460    .  470    .  480    .  490    .  500    .  510    .  520    .  530    .  540    .  550    .  560    .  570    .  580    .  590    .  600    .  610    .  620    .  630    .  640    .  650    .  660    .  670    .  680    .  690    .  700    .  710    .  720    .  730    .  740    .  750    .  760    .  770    .  780    .  790    .  800    .
# Score Template Links and tools%idFirst MGSEQALSEVVESAKERFGRLRHLVQKFLDDDDVPQECLPLLQECAEIWSSYVDACQDITMQAPKEDANRLSKGFLRLNETAFLYYMIVYTLLEDTLPRLKEFSSNKDQNVRNLYGERIQLLHNDPNIERIRNVIENYPKFIQLQTIEPGKLSSMLHFHGDALLLIDVRPRSEFVRAHIKCKNIICIDPASFKDSFTDQQIESVSLITSPHSDITFFSNRDKFKFIILYTDTQLHNNFQQRQTRILAKILSQNSVIKPLSGTKILILENGFSNWVKLGGAYQSSVSETAHLTSSSSTPAFGSPQVPTGLFNQKSLSPNKDKSMPMVSMNTQPLLTTVQRPQLPLYYSDLPIIPQPSPNRNSPTVQKFSPHPPTTLSKLNTPSTIQNKANTVERISPDIRAAQAHAYLPPASNVFSPRIPPLPQQNLSSSRQTILNNSQVLDLDLIVGLENIGNCCYMNCILQCLVGTHDLVRMFLDNTYLNFINFDSSRGSKGLLAKNFAILVNNMHRHGAFTPPNVRTIPVQTIQFKKICGHINPMYSDSMQQDCQEFCQFLLDGLHEDLNQNGSKKHLKQLSDEEERMREKMSIRKASALEWERFLLTDFSAIIDLFQGQYASRLQCQVCEHTSTTYQTFSVLSVPVPRVKTCNILDCFREFTKCERLGVDEQWSCPKCLKKQPSTKQLKITRLPKKLIINLKRFDNQMNKNNVFVQYPYSLDLTPYWARDFNHEAIVNEDIPTRGQVPPFRYRLYGVACHSGSLYGGHYTSYVYKGPKKGWYFFDDSLYRPITFSTEFITPSAYVLFYERIFLast
1 -194.000[O] COG5533 Ubiquitin C-terminal hydrolase  ali  100  1MGSEQALSEVVESAKERFGRLRHLVQKFLDDDDVPQECLPLLQECAEIWSSYVDACQDITMQAPKEDANRLSKGFLRLNETAFLYYMIVYTLLEDTLPRLKEFSSNKDQNVRNLYGERIQLLHNDPNIERIRNVIENYPKFIQLQTIEPGKLSSMLHFHGDALLLIDVRPRSEFVRAHIKCKNIICIDPASFKDSFTDQQIESVSLITSPHSDITFFSNRDKFKFIILYTDTQLHNNFQQRQTRILAKILSQNSVIKPLSGTKILILENGFSNWVKLGGAYQSSVSETAHLTSSSSTPAFGSPQVPTGLFNQKSLSPNKDKSMPMVSMNTQPLLTTVQRPQLPLYYSDLPIIPQPSPNRNSPTVQKFSPHPPTTLSKLNTPSTIQNKANTVERISPDIRAAQAHAYLPPASNVFSPRIPPLPQQNLSSSRQTILNNSQVLDLDLIVGLENIGNCCYMNCILQCLVGTHDLVRMFLDNTYLNFINFDSSRGSKGLLAKNFAILVNNMHRHGAFTPPNVRTIPVQTIQFKKICGHINPMYSDSMQQDCQEFCQFLLDGLHEDLNQNGSKKHLKQLSDEEERMREKMSIRKASALEWERFLLTDFSAIIDLFQGQYASRLQCQVCEHTSTTYQTFSVLSVPVPRVKTCNILDCFREFTKCERLGVDEQWSCPKCLKKQPSTKQLKITRLPKKLIINLKRFDNQMNKNNVFVQYPYSLDLTPYWARDFNHEAIVNEDIPTRGQVPPFRYRLYGVACHSGSLYGGHYTSYVYKGPKKGWYFFDDSLYRPITFSTEFITPSAYVLFYERIF 805
2 -106.000[O] KOG1870 Ubiquitin C-terminal hydrolase  ali follow..  23  2..................................................................................................................................AEGGGCRERPDAETQKSELGPLMRTTLQRGAQWYLIDSRWFKQWKK-YVGFDS----MYNVGEHNLFPGPIDNSGLFSDPESQTLKEHLIDELDYVLLLNWYGCVEGQQPIVRKVVEHGLFVKHCKVEVYLLELKLCE--------------------NSDPTNVLSCHFSKADTIATIEKEMRKLFNIPAERETRLWNKYMSNTYEQLSKLDNTVQDAGLYQGQVLVIEPQNEDGTWPRQTLQSKSSTAPSRNFTTSPKSSASPYSSVSASLIANGDSTSTCGMHSSGVSRGGSGFSASYNCQEPPSSHIQPGLCGLGNLGNTCFMNSALQCLSNTAPLTDYFLKDEYEAEINRDNPLGMKGEIAEAYAELIKQMWSG--------RDAHVAPSMFKTQVGRFAPQFSGYQQQDSQELLAFLLDGLHEDLNRVKKKPYLELKDA------NGRPDAVVAKEAWENHRLRNDSVIVDTFHGLFKSTLVCPECAKVSVTFDPFCYLTLPLPKKTTVALRDCIELFTTMETLGEHDPWYCPNCKKHQQATKKFDLWSLPKILVVHLKRFSYNRDKLDTVVEFPIRLNMSEFVCNL---------------SARPYVYDLIAVSNHYGAMGVGHYTAYAKNKLNGKWYYFDDSNVSLAS-EDQIVTKAAYVLFYQR.. 922
3 -92.300[O] COG5560 Ubiquitin C-terminal hydrolase  ali follow..  33  321..................................................................................................................................................................................................................................................................................................................................................................................................................ENRLDKITSNPSDLVIEIKPIEGNHHWPSNYFAYNKLEPASGTTGLVNLGNTCYMNSALQCLVHIPQLRDYFLYDGYEDEINEENPLGYHGYVARAFSDLVQKLFQNRMSIMQRNA--AFPPSMFKSTIGHFNSMFSGYMQQDSQEFLAFLLDSLHEDLNRIIKKEYTEKPSSPGDDVNDWNVVKKLADDTWEMHLKRNCSVITDLFVGMYKSTLYCPECQNVSITFDPYNDVTLPLPKERTITLDDCLQLFSKPEILGLTDSWYCPTCKEHRQATKQIQLWNTPDILLIHLKRFESQSDKIDATVNFPITLDLSRYVVYKDDPR--------------GLIYDLYAVDNHYGGLGGGHYTAYVKNFADNKWYYFDDSRVTETA-PENSIAGSAYLLFYIR.. 1109
4 -88.400[O] KOG1873 Ubiquitin-specific protease  ali follow..  22  186................................................................................................................................................................................................................................................................................................................................................................................................................KGRSLNNLASSDIEDQCSGSGSITSDIKLEGAVTSDIEARDGYVVRGLVNLGNTCFFNSIMQNLLSLDRLRDHFLK---------ENGSGVGGPLASSLRKLFTETKPEAG------LKSVINPRAFFGSFCSKAPQFRGYDQHDSHELLRCLLDSLSTEESALRKKR------------------------GVSDNDEKSTTLIESVFGGETSSIVSCMECGHSSKVYEPFLDLSLPVPFKKAARIHSADESESKGTQDEDEDSEKVITVK--RDATKKVLINKAPPVLTIHLKRFSQRLSKLNGHVAFKEVIDLRQYMDSRCSGE-------------DPPVYRLAGLVEHSGTMRGGHYVAYVRDSSSTAWYNVSDAYVRQVS-LEKVLHSEAYILFYERI. 957
5 -87.200[O] KOG1867 Ubiquitin-specific protease  ali follow..  18  152....................................................................................................................................................................................................................................................................HRRRILMGKIFRTWFEQSPIGRKKQEEPFQEKIVVKREVKKRRQELEYQVKAELESMPPRKSLRLQGLAQSTIIEIVSVQVPAQTPASPAKDKVLSTSENEISQKVSDSSVKRRPIVTPGVTGLRNLGNTCYMNSVLQVLSHLLIFRQCFLKLDLNQWLAMTASEKTRSCKHPPVTDTVVYQMNECQEKDTGFVCSRQSSLSSGLSGGASKGRKMELIQPK-----EPTSQYISLCHELHTLFQVMWSG--------KWALVSPFAMLHSVWRLIPAFRGYAQQDAQEFLCELLDKIQRELETTGTSLP------------------ALIPTSQRKLIKQVLNVVNNIFHGQLLSQVTCLACDNKSNTIEPFWDLSLEFPERQPCLVTEMLAKFTETEALEG-KIYVCDQCNSKRRAQKQLMICHLPQVLRLHLKRFRWSREKIGVHVGFEEILNMEPYCCRETLKSL----------RPECFIYDLSAVVMHHGGFGSGHYTAYCYNSEGGFWVHCNDSKLSMCT-MDEVCKAQAYILFYTQ.. 677
6 -85.900[O] KOG1864 Ubiquitin-specific protease  ali follow..  21  3.....................................................................................................................................................................................................................................................................................................................................................................................................................................ATGSSQLEKEISTTESVNNANEHYYGLVNFGNTCYCNSVIQALFFCRPFREKVLNYKQTLKKSGASKDNLVTCLADLFHSIASQKRRVG----------TIAPKRFITKLKKENELFDNYMQQDAHEFFNYLINTISETLIQEKIAPATAGLPRSDEKGTSERNGGITVEGNEFLNKSDTTTWIHEIFQGILTNETRCLSCETVSSKDEDFLDLSIDVEQNT--SISHCLRVFSETETLCGDQKYFCETCSSKQEAQKRMRIKKPPQLLALHLKRFKFRHTKLSYRVVFPLELRLFNVS---------------DDAEYGDRMYDLVATVVHCGTPNRGHYITLVKS--NSFWLVFDDDIVEKLEVSSSGMSTDANIQMPPGN. 387
7 -84.000[O] KOG1868 Ubiquitin C-terminal hydrolase  ali follow..  15  24.....................................................................................................................................................EALIETVQRQKEIKLVVTFKSGKFIRIFQLS------------------NNIRSVVLRHCKKRQSHLRLTLKN-NVFLFIDKLSYR---DAKQLNMFLDIIHQNKSQQPMKSD---------DDWSVFESRNMLKEIDKTSFYSICNKPSYQKMPLFMSKSPTHVKKGILENQGGKGQNTLSSDVQTNEDILKEDNPVPNKKYKTDSLKYIQSNRKNPSSLEDLEKDRDLKLGPSFNTNCNGNPNLDETVLATQTLNAKNGLTSPLEPEHSQGDPRCNKAQV----PLDSHSQQLQQGFPNLGNTCYMNAVLQSLFAIPSFADDLLTQGVPWEYIPFEAL----IMTLTQLLALKDFCST--------KIKRELLGNVKKVISAVAEIFSGNMQNDAHEFLGQCLDQLKEDMEKLNATLNTGKECGDENS--------SPQMHVGSAATKVFVCPVVANFEFELQLSLICKACGHAVLKVEPNNYLSINLHQETKLSIQNSLDLFFKEEELE----YNCQMCKQ-KSCVARHTFSRLSRVLIIHLKRYSFNLVKNNEQVYIPKSLSLSSYCNESTKPPEAKELTRNVKMGDPLQAYRLISVVSHIGSPNSGHYISDVYDFQKQAWFTYNDLCVSEISETKEARLHSGYIFFYMH.. 884
8 -79.900[O] KOG1871 Ubiquitin-specific protease  ali follow..  19  5...........................................................................................................................................................................................................................................................................................................................................................................................................................................................RPRGLTNRSNYCYINSILQALLGCSPFYNLLRSIPKQAAVLSEVKVNAMMSFMTNFSSLPSGLRLRLNNLNKGSQSKAFEPTEIYKLWNDSREEHVEGRQEDAEEFLGYVLNKLNDEMLEVIKLIDQEPAEPEDGGDVWQMICNNRNKGSVTRQTDFGRTPVSDIFRGELRSRLQR-EGEHSTDVIQPFFTLQLNIEKAA--SVKEALEILVGRDQLEG---VTGSKTKQEVVAWQQMTLEKLPVVLILHLKYFDYRCTKILKKVDFPVELKIDAKILGS------------KKTSQKQRAYRLFAVVYHDGEASKGHYITDVFHTGYSSWLRYDDSSVKPVSEKHVLQPRVPYLLYYRRS. 379
9 -79.900[Z] KOG2026 Spindle pole body protein - Sad1p  ali follow..  17  105..................................................................................................................................................................................................................................................................................................................................................................................................................DSSLDDIKYVLNPTFTRQEISKLDQLQPKHSRTVDGVLYLPGVVGLNNIKANDYCNVVLHALSHVGPLRDYFLQKQSYAHVV-RPPGDSVFTLVQRFGELMRKMWNPR-----NFKSHVSPHEMLQAVVLWSSKRFQITEQGDPIDFLSWFLNTLHRALKGNKHP-----------------NSSILYKIFLGEMKIYTRKMPPVELDDAAKAQLLATEEYKDQVEDKNFIYLTCDLPPPTDEFRENIIPQVNLYQLLSKFNGTAKEYKTYKANFMKRFEITRLPQFIILYIKRFTKNLEKNPTIVNFPIKVDFGDILGMRQRD-----------KDVKDTKYNLVANIVHDGDPKKGTYRAHILHKANGQWYEMQDLHVTEIL-PQMITLTESYIQIYER.. 478
10 -69.500[O] COG5207 Isopeptidase T  ali follow..  20  302..................................................................................................................................................................................................................................................................................................................................................................................................................QEKIADEKTLVQLQVEQNENWQFRMVDSSGKEFEKLSASKNYGCGLINLGNSCYLNSVIQSLVNGGNWSLDFLGSKFPLDVVYPD-----NNLKCQWIKLLNAMKCE-----PELYPNGIKPTTFKKCIGQNHQEFSSNRQQDAMEFLTFLLDLLDKKFFSSSSS---------------------------------GIPNPNDLVRFMMEDRLQCNICGKVKYSYEPTEAIQIPLEENDEQDMLERIKAYFEGQTIE----FKCANCKEKVTANKKPGFKSLPQTLILNPIRIRLQNVKTSNELSLPGLIDRDDMLDVSSEVPNEEQQQKKDLGYSTAKPYALTAVICHKGSVHSGHYVVFIRKADKWKWVLYNDEKLVAAD-SIEDMKKNGYIYFYTRC. 803
11 -65.200[O] KOG1872 Ubiquitin-specific protease  ali follow..  17  104.............................................................................................................................................................................................................................................................................................................................................................................................................................................................AGLTNLGNTCYMNATVQCLNAVPELRTALSTFSN----DGTDTMSTAFSISSAMKSIFAQMEKGT----------TVTPIVLLQALHRASPQFATYRQQDANECWAEILKMLQQKLRPKNQEPSNTV-------------------------QKRHSSFIDQFFGGTFEVKMSSEEDPDETVTSENFLQLSCFISMDVK-YMQSGLKSKMKEQLV-----KKSETLGRDAKYIRTYLVSRLPAYLTVQFVRFQYKGKKVLKDIKFPIDFDAFELCTPELQNKLCPMRSKDDLGSNNSGYYTLQAVLTHKGSSSSGHYVAWVRSS-GDVWFKFDDDEVSAVATDEILRLSCAYVLLYAP.. 469
12 -63.700[O] KOG0944 Ubiquitin-specific protease UBP14  ali follow..  12  22...............................................................................................................................................DQKIFKDQCAYCFKDPHGK-LYISLKNYHAFCREHAEIYGTTSGNTLFVQFESTKKIIEERTDGEPTSKMTKLFEFEDKYCVVVHPEYSQQVKNVQLPEIAEAIAQIANTTSAERLSL---------LSSTSNAWDAEIKLITKHQNLEQQDNGKHLALTGWTCEVEGCGLNDN----------TDGAVRCGRSQFLSDGKKTNGNGHMQDYFDSTRFPLVVKLGTISSNLELIDVYSYDEDDAVIDPNLEKHLKHFGLDPTKMEKTAKSTMEMELDMNEKWEWSKCTEDGLLLEPIFGPGYTGLVNTGSSCYMNSVLQALVTVDSFQTRYGEQGLETLVNCPLD-KLHNDFNAQFSKVVRAMLSGDYSSEMDPTNNHIKPLQFKRVAAGNHRDFSTSKQQDVEEYIRFLFEKIAENSRTEVIDP-------------------------------------TDSFKFKAINRFEDRGTRRVRYTDQEEMLIRLPISGDYISSGTPSARGEVDPNLVASIVEMGFSNHQAKYALKQVPTVAEAVEWLFANMDSIPVESAAVGLSSDAPEP--------------SVTESATQKTFKDGGEKYKLIGMISHMGRPDSGHYVAHMLK--EGKWVLFNDEKVALS---QDPPKKLAYVYLYKRI. 757
13 -56.200[O] COG5077 Ubiquitin carboxyl-terminal hydrolase  ali follow..  25  203...................................................................................................................................................................................................................................................................................................................................................................................................................................................DYDSKIATGYVGLKNQGATCYMNSLLQSLYIIHAFRRIVYQIPTDSPQGKDS-------IAYALQRCFYNLQFMN---------EPVSTTELTKSFG---DSLDSFMQHDVQEFNRVLQDNLERSMRDTKVE-----------------------------------NALTNLFVGKMKSYIACVNVNFESARSEDYWDIQLNV--KGMKNLEDSFRSYIQVETLEGDNCYFADTYGF-QEAKKGVIFESFPPILHLQLKRFEYDFEKINDRYEFPLEFDAKAFLSPEADQS-------------QNCEYVLYGVLVHSGDLHNGHYYALLKTEKDGPWYKYDDTRVTRATLREVLEENSAYMLLYLR.. 527
14 -47.900[O] KOG1865 Ubiquitin carboxyl-terminal hydrolase  ali follow..  22  2...............................................................................................................................................................................................................................................................................................................................................................................EDDSLYLGGEWQFNHFSKLTSSRPDAAFAEIQRTSLPEKSQLSTETRVDFCDDLAPVARQLAPREKLPLSSRRPAAVGAGLQNMGNTCYVNASQQCLTYIPPLANYML-------------------------------------------------------------------------------------------------------------------------------------------SREHSQTCHRHKCCMLCTMEAHITW-PLHIPGHVIQPSQALAAGFHRGKQEAALEFLMFTVDAMKKACLPGHKQILILVWKRFSDTGNKIAKNVQYPECLDMQPYM---------------SQQNTGPLVYVLYAVLVHAGSCHNGHYFSYVKVQ-EGQWYKMDDAEVTASG-ITSVLSQQAYVLFYIQ.. 282
15 -13.600[V] KOG1717 Dual specificity phosphatase  ali follow..  13  2..................................................................................................................................IDTLRPVPFASEMAISKTVAWLNEQLELGNERLLLMDCRPQELYESSHIESAINVAIPGIMLRR--LQKGNLPVRALFTRGEDRDRFTRRCGTDTVVLYDESSSDWNENTGGESVLGLLLKKLK-----EGCRAFYLEGGFSKFQAEFSLHCETNLDGSC-----------------------------------------------------------------------------SSSSPPLPVLGLGGLRISSDSSSDIESDLDRDPNSATDSDGSPLSNSQPSFPVEILPFLYLGCAKDSTNLDVLEEFGIKYILNVTPNLYKQIPIS--HWSQNLSQFFPEASFIDEARGKNCISRSVTVTVAYLMQKLNLSMNDAYDIVKMKKSNISPNNFMGQLLDFERTLGLSSPCDNRV................................................................................................................................................................................................................................................................. 357
16 -9.570[C] COG1150 Heterodisulfide reductase, subunit C  ali follow..  13  21......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ELSELVEPVFEEEEVLSVQACYQCGTCTGSCPSGRRTSYR-TRL----IMRKLQLGLVDEVIKSDELWMCTTCYTYERCPRGVKIVD----AVKAARNLAAKKGYMAKAHR................................................................................................ 123
FFAS is supported by the NIH grant R01-GM087218-01
1 4 6 8 3 9   jobs submitted since Jan 1, 2011
Comments and questions to: webmaster
Selected papers from Godzik Lab
Ying Zhang, Ines Thiele, Dana Weekes, Zhanwen Li, Lukasz Jaroszewski, Krzysztof Ginalski, Ashley Deacon, John Wooley, Scott Lesley, Ian Wilson, Bernhard Palsson, Andrei Osterman, Adam Godzik. Three-Dimensional Structural View of the Central Metabolic Network of Thermotoga maritima. Science. 2009 Sep 18;325(5947):1544-9.

Mayya Sedova, Mallika Iyer, Zhanwen Li, Lukasz Jaroszewski, Kai W Post, Thomas Hrabe, Eduard Porta-Pardo, Adam Godzik Cancer3D 2.0:: interactive analysis of 3D patterns of cancer mutations in cancer subsets. Nucleic Acids Research, gky1098 2018; Published on November 8 2018.

Godzik A. Fold recognition methods. Methods Biochem Anal. 2003;44:525-46. Review.